Join to View Full Profile
3855 Health Sciences DrLa Jolla, CA 92093
Phone+1 858-534-3804
Dr. Cohen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board-certified oncologist and cancer researcher. I care for patients with all types of head and neck cancers, including esophageal, thyroid and salivary gland cancers.
Much of my work has focused on squamous cell carcinomas and cancers of the thyroid, salivary gland, and HPV-related oropharyngeal cancers. As a physician-scientist, he is especially interested in developing novel therapies and understanding mechanisms of sensitivity or resistance; cancer screening; and using medication and other agents to delay or prevent cancer (chemoprevention). Additionally, I was recently appointed chair of the National Cancer Institute Head and Neck Cancer Steering Committee, which oversees NCI-funded clinical research in this disease.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 1999 - 2002
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1996 - 1999
University of Toronto Faculty of MedicineClass of 1990
Certifications & Licensure
CA State Medical License 2014 - 2026
IL State Medical License 1999 - 2026
MA State Medical License 2011 - 2017
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) Start of enrollment: 2004 Nov 01
- Rapamycin With Grapefruit Juice for Advanced Malignancies Start of enrollment: 2006 Sep 01
- Erlotinib Prevention of Oral Cancer (EPOC) Start of enrollment: 2006 Nov 03
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsMulticenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the P...Kevin C Flanagan, Jon Earls, Jeffrey Hiken, Rachel L Wellinghoff, Michelle M Ponder
Journal for Immunotherapy of Cancer. 2024-11-03 - Low PD-L1 expression, MAP2K2 alterations, and enriched HPV gene signatures characterize brain metastases in head and neck squamous cell carcinoma.Michael J Dennis, Dean C Pavlick, Alec Kacew, Michael Wotman, Laura E MacConaill
Journal of Translational Medicine. 2024-10-22 - 1 citationsAn Era of Advances in Systemic Therapies for Advanced Thyroid Cancer.Karen M Yun, Ezra E W Cohen
JCO Oncology Practice. 2024-07-01
Lectures
- Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic ...2019 ASCO Annual Meeting - 6/1/2019
- Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) i...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- ECHO-310: A phase 3, randomized trial of epacadostat + nivolumab + chemo vs EXTREME as first-line treatment of recurrent/metastatic SCCHN.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Join now to see all
Press Mentions
Q&A: Exploring the Implications of CHIP on Oncology Patient CareFebruary 14th, 2025- Artera Partners with Tempus to Expand AI Cancer Test AccessFebruary 13th, 2025
- Tempus Scores a Win with Blue Cross PlansDecember 18th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
